HK Stock Market Move | CHINARES PHARMA (03320) rose more than 3%, with its subsidiary China Resources Double-Crane Pharmaceutical potentially acquiring a stake in Lier Chemical.

CHINARES PHARMA (03320) rose more than 3%, as of the time of writing, it was up 2.8% at 4.77 Hong Kong dollars, with a turnover of 23.6159 million Hong Kong dollars. On the news front, on July 15, CHINARES PHARMA announced that its indirectly non-wholly owned subsidiary China Resources Double-Crane Pharmaceutical Co., Ltd. (China Resources Double-Crane Pharmaceutical) had participated in the public solicitation of transfer initiated by Sichuan Jiuyuan Investment Holdings Group Co., Ltd. (Jiuyuan Group) and Sichuan Huacai Technology Co., Ltd. (Huacai Technology, together with Jiuyuan Group collectively referred to as the "Seller"), to transfer a total of 188,102,749 shares of Lier Chemical Co., Ltd. (Lier Chemical, a company listed on the Shenzhen Stock Exchange (stock code: 002258)), representing approximately 23.50% equity interest in Lier Chemical (potential acquisition). Lier Chemical is mainly engaged in the research, development, production, and sales of efficient, low-toxic, low-residue, and safe pesticide active ingredients and pesticide formulations. On July 15, 2026, China Resources Double-Crane Pharmaceutical received notice from the Seller confirming its ranking as the first intended transferee in the above-mentioned public solicitation of transfer. As of the date of this announcement, China Resources Double-Crane Pharmaceutical does not hold any shares in Lier Chemical. Since 2022, the Group has been continuously expanding its presence in the field of synthetic biology through China Resources Double-Crane Pharmaceutical, and has currently established seven major technology platforms, focusing on the areas of raw material drug intermediates, new health foods, plant protection and animal husbandry, and new materials and new energy. The Company believes that the potential acquisition aligns with the overall strategic planning of the Group, and will drive the industrialization of technology products in the field of synthetic biology.